Immunotherapy tends to give an all-new beginning to the patient and stands head-to-head when compared with standard chemotherapy and the immunotherapy drug nivolumab, Clinical trial research has found that people with squamous non-small cell lung cancer who were treated with nivolumab have lived 3.2 months on an average more than those who were treated with chemotherapy. Squamous non-small cell lung cancer considers for about 25 to 30% of malignancies of all lungs.

Results of the trial reported by the New England Journal of Medicine on 31 ^st May 2015 were presented at the annual meeting of American Society of Clinical Oncology 2015.

Immunotherapy normally helps the immune system live long. After treatment of chemotherapy ends, rapidly diving cells of both healthy and cancerous ones, and starts with the side effects of hair loss and nausea. In case of immunotherapy, side effects are slightly different which mostly reflects like skin rashes or diarrhea. Chemo tumors may shrink quickly, but immunotherapy can take a long time and sometimes tumor may even appear to grow before getting smaller. Immunotherapy is already at play for treating some types of cancers, even at the very advanced of the stages.

The important aspect to be considered is that the clinical immunotherapies should firstly understand the interaction between the both (cancer cell and an immune cell). Because applying immunotherapy drug is virtually diminishing the cancer cell and letting natural defenses heal the immune system of the body.

It again depends on the person’s health condition and the severity of cancer cells. The team of doctors can apply immunotherapy, or chemo, or a combination of two immunotherapies. Immunotherapy treatment could be the future arena for people with cancer. However, therapists need the approval to get started depending upon the cancer stage level of the inmate. As an incisive prevailing science is huge and innovative, there is a great leap forward on the path in curing all cancers.